Probiotics for inflammatory bowel disease: Is there sufficient evidence?
Inflammatory bowel disease (IBD) refers to chronic inflammatory disorders of the gut. Ulcerative colitis (UC) and Crohn’s disease (CD) are two subtypes of IBD. Evidence suggests that the intestinal microbiota plays a role in the pathogenesis of IBD, so probiotics have garnered a lot of interest as a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2024-04-01
|
| Series: | Open Life Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/biol-2022-0821 |
| _version_ | 1797219153070784512 |
|---|---|
| author | Ma Yueying Yang Dandan Huang Jin Liu Kunli Liu Huirong Wu Huangan Bao Chunhui |
| author_facet | Ma Yueying Yang Dandan Huang Jin Liu Kunli Liu Huirong Wu Huangan Bao Chunhui |
| author_sort | Ma Yueying |
| collection | DOAJ |
| description | Inflammatory bowel disease (IBD) refers to chronic inflammatory disorders of the gut. Ulcerative colitis (UC) and Crohn’s disease (CD) are two subtypes of IBD. Evidence suggests that the intestinal microbiota plays a role in the pathogenesis of IBD, so probiotics have garnered a lot of interest as a potential treatment or prevention for IBD. However, clinical evidence of the efficacy of probiotics is still debatable. We performed a literature review. An advanced search considered clinical studies on probiotic for IBD from inception to 2023 in PubMed, Embase, Cochrane Library, and Web of Science. In the treatment of UC with probiotics, only Escherichia coli Nissle 1917 for maintenance treatment of UC in remission, and Bifidobacterium and VSL#3 for induction of remission in patients with mild to moderately active UC have shown strong evidence. Currently, there are no definitive conclusions regarding the effectiveness of probiotics in CD. The mechanism of probiotic treatment for IBD may be related to reducing oxidative stress, repairing the intestinal barrier, regulating intestinal flora balance, and modulating intestinal immune response. Differences in the benefits of probiotics between CD and UC may be attributable to the different lesion extent and immune-mediated pathophysiology. More robust randomized clinical trials are required to validate the efficacy and safety of diverse probiotic strains in IBD. |
| first_indexed | 2024-04-24T12:29:07Z |
| format | Article |
| id | doaj.art-ed5394f42e434995ace42259eb3fee21 |
| institution | Directory Open Access Journal |
| issn | 2391-5412 |
| language | English |
| last_indexed | 2024-04-24T12:29:07Z |
| publishDate | 2024-04-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Life Sciences |
| spelling | doaj.art-ed5394f42e434995ace42259eb3fee212024-04-08T07:35:33ZengDe GruyterOpen Life Sciences2391-54122024-04-01191135011110.1515/biol-2022-0821Probiotics for inflammatory bowel disease: Is there sufficient evidence?Ma Yueying0Yang Dandan1Huang Jin2Liu Kunli3Liu Huirong4Wu Huangan5Bao Chunhui6Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai200437, ChinaHong Kong Baptist University, Hong Kong999077, ChinaYueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai200437, ChinaYueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai200437, ChinaYueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai200437, ChinaYueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai200437, ChinaYueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai200437, ChinaInflammatory bowel disease (IBD) refers to chronic inflammatory disorders of the gut. Ulcerative colitis (UC) and Crohn’s disease (CD) are two subtypes of IBD. Evidence suggests that the intestinal microbiota plays a role in the pathogenesis of IBD, so probiotics have garnered a lot of interest as a potential treatment or prevention for IBD. However, clinical evidence of the efficacy of probiotics is still debatable. We performed a literature review. An advanced search considered clinical studies on probiotic for IBD from inception to 2023 in PubMed, Embase, Cochrane Library, and Web of Science. In the treatment of UC with probiotics, only Escherichia coli Nissle 1917 for maintenance treatment of UC in remission, and Bifidobacterium and VSL#3 for induction of remission in patients with mild to moderately active UC have shown strong evidence. Currently, there are no definitive conclusions regarding the effectiveness of probiotics in CD. The mechanism of probiotic treatment for IBD may be related to reducing oxidative stress, repairing the intestinal barrier, regulating intestinal flora balance, and modulating intestinal immune response. Differences in the benefits of probiotics between CD and UC may be attributable to the different lesion extent and immune-mediated pathophysiology. More robust randomized clinical trials are required to validate the efficacy and safety of diverse probiotic strains in IBD.https://doi.org/10.1515/biol-2022-0821probioticsinflammatory bowel diseaseulcerative colitiscrohn’s diseaseintestinal microbiomegut health |
| spellingShingle | Ma Yueying Yang Dandan Huang Jin Liu Kunli Liu Huirong Wu Huangan Bao Chunhui Probiotics for inflammatory bowel disease: Is there sufficient evidence? Open Life Sciences probiotics inflammatory bowel disease ulcerative colitis crohn’s disease intestinal microbiome gut health |
| title | Probiotics for inflammatory bowel disease: Is there sufficient evidence? |
| title_full | Probiotics for inflammatory bowel disease: Is there sufficient evidence? |
| title_fullStr | Probiotics for inflammatory bowel disease: Is there sufficient evidence? |
| title_full_unstemmed | Probiotics for inflammatory bowel disease: Is there sufficient evidence? |
| title_short | Probiotics for inflammatory bowel disease: Is there sufficient evidence? |
| title_sort | probiotics for inflammatory bowel disease is there sufficient evidence |
| topic | probiotics inflammatory bowel disease ulcerative colitis crohn’s disease intestinal microbiome gut health |
| url | https://doi.org/10.1515/biol-2022-0821 |
| work_keys_str_mv | AT mayueying probioticsforinflammatoryboweldiseaseistheresufficientevidence AT yangdandan probioticsforinflammatoryboweldiseaseistheresufficientevidence AT huangjin probioticsforinflammatoryboweldiseaseistheresufficientevidence AT liukunli probioticsforinflammatoryboweldiseaseistheresufficientevidence AT liuhuirong probioticsforinflammatoryboweldiseaseistheresufficientevidence AT wuhuangan probioticsforinflammatoryboweldiseaseistheresufficientevidence AT baochunhui probioticsforinflammatoryboweldiseaseistheresufficientevidence |